Company Profile

Asia Cell and Gene Therapeutics Group (aCGT) was founded in 2016 by Jeff Qi Nianmin, Professor of Shanghai Jiao Tong University and former Senior Process Development Scientist at Bayer US. 

aCGT is dedicated to the development of cell and gene therapeutic products for various indications. Our cell therapeutic products are based on umbilical cord mesenchymal stem cells (ucMSC), induced pluripotent stem cells (iPSC), natural killer (NK) cells, etc. With or without additional genetic manipulation, our products demonstrate potency in combating such treatment-resistant diseases as ankylosing spondylitis, liver cirrhosis, acute respiratory distress syndrome (ARDS) and cancer. 

Over the years, aCell has built a strong R&D team for discovery, CMC and clinical development. With expertise in these areas, aCGT has obtained four IND approvals for ucMSC products, which are under clinical investigation. aCell is also speeding up the development of iPSC-based cellular products towards the goal of bringing economic availability to more patients.

aCGT runs a cGMP facility for manufacturing of clinical grade cellular products (800 m2) and 4000 m2 of pilot scale cGMP manufacturing facility. An additional 6000 m2 of batch production scale cGMP manufacturing facility is nearly completed in the scenic area of Anji County, Zhejiang Province. Besides, aCGT is planning a manufacturing site in Taiwan of China for international affairs.

Besides, aCGT is devoted to the integration of intellectual resources and outcomes from institutions, universities and industry, thus greatly facilitating the development of innovative cellular products and benefiting the society. A network incorporating aCGT and some institutions or laboratories has been formed to this end.